Enterprise Value
1.659B
Cash
307.6M
Avg Qtr Burn
N/A
Short % of Float
13.43%
Insider Ownership
2.04%
Institutional Own.
50.78%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Afrezza® (insulin human) Inhalation Powder Details Diabetes, Type 1 diabetes, Type 2 diabetes | Phase 4 Update | |
Tyvaso DPI (Treprostinil Technosphere®) (inhaled treprostinil) Details Pulmonary arterial hypertension, Heart disease | Approved Quarterly sales | |
Afrezza® (insulin human) Inhalation Powder Details Type 1 diabetes, Diabetes, Type 2 diabetes | Phase 3 Data readout | |
Clofazimine inhalation suspension (MNKD 101) Details Nontuberculous mycobacterial lung disease, Lung disease | Phase 3 Initiation | |
MNKD 201 (nintedanib DPI) Details Lung disease, Idiopathic pulmonary fibrosis | Phase 1 Data readout |